推荐产品
等級
CP
蒸汽密度
1.27 (vs air)
蒸汽壓力
25 mmHg ( 20 °C)
形狀
liquid
存貨情形
available only in Japan
濃度
55%
密度
1.15 g/mL at 25 °C (lit.)
SMILES 字串
[H+].[F-]
InChI
1S/FH/h1H
InChI 密鑰
KRHYYFGTRYWZRS-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
訊號詞
Danger
危險分類
Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A
儲存類別代碼
6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
International journal of cardiology, 184, 163-169 (2015-02-24)
We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the
European journal of heart failure, 17(7), 735-742 (2015-04-29)
Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after
Circulation, 131(5), 459-468 (2014-12-04)
Muscle sympathetic activation in heart failure with reduced ejection fraction (HFrEF) has been attributed, on the basis of multiunit recordings, to attenuated inhibitory feedback from stretch-sensitive cardiopulmonary mechanoreceptors. However, such preparations integrate 2 populations of single units exhibiting directionally opposite
Journal of the American College of Cardiology, 65(4), 339-351 (2015-01-31)
Secretoneurin (SN) levels are increased in patients with heart failure (HF), but whether SN provides prognostic information and influences cardiomyocyte function is unknown. This study sought to evaluate the merit of SN as a cardiovascular biomarker and assess effects of
JACC. Heart failure, 2(1), 84-92 (2014-03-14)
Impaired cardiac isoform of sarco(endo)plasmic reticulum Ca(2+) ATPase (SERCA2a) activity is a key abnormality in heart failure patients with reduced ejection fraction. The CUPID 2 (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) trial is
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门